Sudarshan Pharma Industries IPO Details

Bookbuilding IPO | ₹50 Cr | Listed at BSE SME | Thu, Mar 9, 2023 - Tue, Mar 14, 2023

Sudarshan Pharma Industries IPO Logo

Sudarshan Pharma Industries IPO is a book build issue of ₹50.10 crores. The issue is entirely a fresh issue of 0.69 crore shares of ₹50.10 crore.

Sudarshan Pharma Industries IPO bidding started from Mar 9, 2023 and ended on Mar 14, 2023. The allotment for Sudarshan Pharma Industries IPO was finalized on Mar 17, 2023. The shares got listed on BSE SME on Mar 22, 2023.

Sudarshan Pharma Industries IPO price band is set at ₹73 per share. The lot size for an application is 1,600. The minimum amount of investment required by an retail is ₹1,16,800 (1600 shares) (based on upper price). The minimum lot size for investment in HNI is 2 lots (3,200 shares), amounting to ₹2,33,600.

Gretex Corporate Services Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is Gretex Share Broking Pvt.Ltd..

Refer to Sudarshan Pharma Industries IPO RHP for detailed Information.

IPO Open

Thu, Mar 9, 2023

IPO Close

Tue, Mar 14, 2023

Issue Price

₹73 per share

Market Cap (Pre-IPO)

₹175.68 Cr

IPO Details

IPO Date9 to 14 Mar, 2023
Listed onWed, Mar 22, 2023
Face Value10 per share
Price Band₹71 to ₹73
Issue Price₹73 per share
Lot Size1,600 Shares
Sale TypeFresh capital only
Issue TypeBookbuilding IPO
Listing AtBSE SME

Total Issue Size68,62,400 shares
(agg. up to ₹50 Cr)
Reserved for Market Maker
3,44,000 shares
(agg. up to ₹3 Cr)
Gretex Share Broking Pvt.Ltd.
Fresh Issue
(Ex Market Maker)
65,18,400 shares
(agg. up to ₹48 Cr)
Net Offered to Public65,18,400 shares
(agg. up to ₹48 Cr)
Share Holding Pre Issue95,46,998 shares
Share Holding Post Issue1,29,86,998 shares
BSE Script Code 543828
ISININE00TV01015

IPO Timetable

Issue Reservation

Sudarshan Pharma Industries IPO comprises a total issue size of 68,62,400 shares. The net offer to the public is 65,18,400 shares, after excluding 3,44,000 shares allotted on a firm basis. Of the Net offer 13,02,400 (19.98%) are allocated to QIB, 15,64,800 (24.01%) allocated to NII 36,51,200 (56.01%) allocated to RII.

Investor Category Shares Offered % of Net Issue% of Total Issue
QIB Shares Offered 13,02,40019.98%18.98%
  − Anchor Investor Shares Offered 7,80,80011.38%
  − QIB (Ex. Anchor) Shares Offered 5,21,6007.60%
NII (HNI) Shares Offered 15,64,80024.01%22.80%
Retail Shares Offered 36,51,20056.01%53.21%
Firm Reservations
Market Maker Shares Offered 3,44,0005.01%
Total Shares Offered 68,62,400100.00%100.00%

IPO Lot Size

Investors can bid for a minimum of 1,600 shares and in multiples thereof. 

Application Lots Shares Amount
Retail (Min) 1 1,600 ₹1,16,800
Retail (Max) 1 1,600 ₹1,16,800
HNI (Min) 2 3,200 ₹2,33,600
IPO Subscription Details

IPO Anchor Investors

Sudarshan Pharma Industries IPO raises ₹5.70 crore from anchor investors. Sudarshan Pharma Industries IPO Anchor bid date is March 8, 2023.
📝 Anchor Investors Letter (PDF)

Bid DateWed, Mar 8, 2023
Shares Offered7,80,800
Anchor Portion (₹ Cr.)5.70
Anchor lock-in period end date for 50% shares (30 Days)Sun, Apr 16, 2023
Anchor lock-in period end date for remaining shares (90 Days)Thu, Jun 15, 2023

About Sudarshan Pharma Industries Ltd.

Incorporated in 2008, Mumbai based Sudarshan Pharma Industries Limited (SPIL) has a contract manufacturing facility to source and supply generic formulations. It is also engaged in import & export activities, and supply of specialty chemicals, API (Active Pharmaceutical Ingredients), and Intermediates. Based on clients' specifications and requirements, they outsource the manufacturing facility from the suppliers in India and abroad.

The generic products supplied by the company have a wide application in paint, food, pharma, and adhesive industry. The company is involved in a contract manufacturing facility, supply and outsource of medicines and pharma formulation to hospitals, NGO, government and healthcare institutes. SPIL has 50 pharma formulations which are supplied under the brand name in the form of tablets, ointment, capsules, and injectable.

The company has its own sales force and distribution network in 5 states for ethical marketing of pharmaceutical formulation & products under the brand name in Indian and international markets. It also offers formulation development and QC services and provides customised solutions.

The competitive strengths of the company are:

1. Customer-centric and order-driven business model
2. Wide range of product offerings
3. Contract manufacturing facility arrangements
4. Strong distribution, marketing, and sales network
5. Diversified business operations

Company Financials (Restated Consolidated)

Period Ended30 Sep 202231 Mar 202231 Mar 2021
Assets164.02137.5299.26
Total Income195.90357.56193.73
Profit After Tax3.615.302.67
NET Worth51.0929.7822.51
Reserves and Surplus39.9720.0312.96
Total Borrowing49.4130.5929.77
Amount in ₹ Crore

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects Est Amt (₹ Cr.)
1 To set up a dedicated manufacturing facility for Pharmaceutical Business 12.50
2 Distribution and Warehousing Centre‘s & Purchase of Corporate Office 4.50
3 Additional Working Capital 5.25
4 General Corporate Expenses 2.80

Key Performance Indicator (KPI)

KPI
ROE17.81
ROCE38.59
Debt/Equity1.09
RoNW17.81
PAT Margin1.49%
Pre IPOPost IPO
EPS (₹)5.52
P/E (x)24.33
Promoter Holding80.28%
Market Cap175.68 Cr.
Mr. Hemal Vasantrai Mehta and Mr. Sachin Vasantrai Mehta are the Promoters of the company.

IPO Review

[Dilip Davda]
SPIL which failed to sail through its maiden IPO in June 2019 is trying for the second time for nearly double the amount. It is spending whooping Rs. 7.90 cr. (over 10 times projected for the first try) for this IPO process. It has changed the lead manager for this offer and the list of listed peers. Higher borrowings (Rs. 49.41 cr.), and tax notices of Rs. 7.41 cr. (excluding interest/penalty thereon) raises concern. Though it has posted growth in its financial data, it is fully mirrored including the near-term positives in the asking price. Off late we are witnessing a faded out of fancy for the pharma/healthcare segment post-pandemic. There is no harm in skipping this “High-Risk/Low-Return” bet.
Read detail review...

Sudarshan Pharma Industries IPO Recommendations

Review BySubscribeMay ApplyNeutralAvoid
Brokers0001
Members1005

Sudarshan Pharma Industries IPO Subscription Status (Bidding Detail)

The Sudarshan Pharma Industries IPO is subscribed 1.06 times on March 14, 2023 7:02:00 PM (Day 4). The public issue subscribed 1.2 times in the retail category, 1.01 times in the QIB category, and 0.81 times in the NII category. Check Day by Day Subscription Details (Live Status)

CategorySubscription (times)Shares OfferedShares bid for
QIB1.015,21,6005,24,800
NII*0.8119,08,80015,50,400
Retail1.236,51,20043,66,400
Total1.0660,81,60064,41,600

Total Application : 3,005

*Market Maker portion is not included to NII/HNI.

IPO Expenses

# Issue Expenses Est Amt (₹ Cr.)
1 Lead Manger Fees including Underwriting Commission 0.18
2 Market Making Charges for first year of Listing 0.04
3 Fees Payable to Registrar to the Issue 0.01
4 Fees Payable to Advertising and Marketing Expenses 0.35
5 Fees Payable to Regulators including Stock Exchanges 0.02
6 Payment for Printing & Stationery, Distribution, Postage, etc 0.02
7 Others (Fees Payable to Peer Review Auditor, Fees to Legal Advisors, Marketing Expenses, Brokerage, Processing Fees for Application and Miscellaneous Expenses) 0.14

Listing Day Trading Information

Price DetailsBSE SME
Final Issue Price73.00
Open73.00
Low69.35
High73.25
Last Trade69.35

Check IPO Performance…

IPO Registrar

Kfin Technologies Ltd.

Contact Details

Sudarshan Pharma Industries Ltd. Address
301,3rd Floor, Aura Biplex,
Above Kalyan Jewellers S. V. Road, Borivali (West)
Mumbai - 400092
Mumbai, Maharashtra
Open an Instant Account with Zerodha

IPO FAQs

Sudarshan Pharma Industries IPO is a SME IPO of 68,62,400 equity shares of the face value of ₹10 aggregating up to ₹50 Crores. The issue is priced at ₹73 per share. The minimum order quantity is 1600.

The IPO opens on Thu, Mar 9, 2023, and closes on Tue, Mar 14, 2023.

Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.

Zerodha customers can apply online in Sudarshan Pharma Industries IPO using UPI as a payment gateway. Zerodha customers can apply in Sudarshan Pharma Industries IPO by login into Zerodha Console (back office) and submitting an IPO application form.

Steps to apply in Sudarshan Pharma Industries IPO through Zerodha

  1. Visit the Zerodha website and login to Console.
  2. Go to Portfolio and click the IPOs link.
  3. Go to the 'Sudarshan Pharma Industries IPO' row and click the 'Bid' button.
  4. Enter your UPI ID, Quantity, and Price.
  5. Submit IPO application form.
  6. Visit the UPI App (net banking or BHIM) to approve the mandate.

Visit Zerodha IPO Application Process Review for more detail.

The Sudarshan Pharma Industries IPO opens on Thu, Mar 9, 2023 and closes on Tue, Mar 14, 2023.

Sudarshan Pharma Industries IPO lot size is 1600, and the minimum amount required for application is ₹1,16,800.

You can apply in Sudarshan Pharma Industries IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

The finalization of Basis of Allotment for Sudarshan Pharma Industries IPO will be done on Friday, March 17, 2023, and the allotted shares will be credited to your demat account by Tue, Mar 21, 2023. Check the Sudarshan Pharma Industries IPO allotment status.

The Sudarshan Pharma Industries IPO listing date is on Wed, Mar 22, 2023.

Compare: